KR20220092868A - 제1형 간신증후군 및 낮은 평균 동맥압 환자의 치료 방법 - Google Patents

제1형 간신증후군 및 낮은 평균 동맥압 환자의 치료 방법 Download PDF

Info

Publication number
KR20220092868A
KR20220092868A KR1020227013054A KR20227013054A KR20220092868A KR 20220092868 A KR20220092868 A KR 20220092868A KR 1020227013054 A KR1020227013054 A KR 1020227013054A KR 20227013054 A KR20227013054 A KR 20227013054A KR 20220092868 A KR20220092868 A KR 20220092868A
Authority
KR
South Korea
Prior art keywords
patient
terripresin
days
administration
hrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227013054A
Other languages
English (en)
Korean (ko)
Inventor
쿠람 자밀
스티븐 크리스 파파스
피터 토이버
Original Assignee
말린크로트 호스피탈 프로덕츠 아이피 언리미티드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 말린크로트 호스피탈 프로덕츠 아이피 언리미티드 캄파니 filed Critical 말린크로트 호스피탈 프로덕츠 아이피 언리미티드 캄파니
Publication of KR20220092868A publication Critical patent/KR20220092868A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020227013054A 2019-10-30 2020-10-29 제1형 간신증후군 및 낮은 평균 동맥압 환자의 치료 방법 Pending KR20220092868A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928152P 2019-10-30 2019-10-30
US62/928,152 2019-10-30
PCT/IB2020/060185 WO2021084483A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Publications (1)

Publication Number Publication Date
KR20220092868A true KR20220092868A (ko) 2022-07-04

Family

ID=73060034

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227013054A Pending KR20220092868A (ko) 2019-10-30 2020-10-29 제1형 간신증후군 및 낮은 평균 동맥압 환자의 치료 방법

Country Status (10)

Country Link
US (1) US20210128676A1 (https=)
EP (1) EP4051310A1 (https=)
JP (1) JP2023500654A (https=)
KR (1) KR20220092868A (https=)
CN (1) CN114980914A (https=)
AU (1) AU2020373408A1 (https=)
BR (1) BR112022006329A2 (https=)
CA (1) CA3159575A1 (https=)
MX (1) MX2022004157A (https=)
WO (1) WO2021084483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019089A (ko) * 2021-06-07 2024-02-14 말린크로트 파마슈티칼스 아일랜드 리미티드 간신장 증후군 1형 환자의 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203036A1 (en) * 2010-07-14 2015-07-02 Cumberland Emerging Technologies, Inc Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1

Also Published As

Publication number Publication date
CA3159575A1 (en) 2021-05-06
EP4051310A1 (en) 2022-09-07
US20210128676A1 (en) 2021-05-06
MX2022004157A (es) 2022-07-19
JP2023500654A (ja) 2023-01-10
CN114980914A (zh) 2022-08-30
AU2020373408A1 (en) 2022-04-21
BR112022006329A2 (pt) 2022-08-16
WO2021084483A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
US11352405B2 (en) GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
US20240366710A1 (en) Method of treating patients with hepatorenal syndrome type 1
Jochberger et al. Course of vasopressin and copeptin plasma concentrations in a patient with severe septic shock
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
KR20220092868A (ko) 제1형 간신증후군 및 낮은 평균 동맥압 환자의 치료 방법
US20200237856A1 (en) Method of treating patients with hepatorenal syndrome type 1
KR20240019089A (ko) 간신장 증후군 1형 환자의 치료 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902